Veracyte, Inc. (VCYT)
POSITIVEFundamental
74
Kurs
$43.65
Marktkapitalisierung
$3.32B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$562M
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$114M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$127M
Gesamtes Eigenkapital
$1.31B
Gesamtverbindlichkeiten
$96M
Current Ratio
9.16
Zinsdeckungsgrad
-
Schulden/EBITDA
0.51
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$43.39
Aktueller Kurs
$43.65
Sicherheitsmarge
-0.6%
Innerer-Wert-Spanne
$28.21 - $58.58
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
29.62
ROE
5.1%
P/B-Verhältnis
2.40
P/FCF
20.08
Bruttomarge
71.7%
ROIC
5.9%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
5.9%
WACC
15.2%
ROIC − WACC
-9.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (20)
- EPS shows upward trend
- Price CAGR 18.52%
- ROIC 5.9%
- Gross Margin 71.7%
- P/FCF 20.08
- P/B Ratio 2.40
- Debt/Equity ratio
- Operating Margin 18.8%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 8.6%
- Revenue Growth 5Y 34.5%
- Analyst Consensus 84% Buy
- Earnings Surprise avg 93.2%
- Earnings Quality (OCF/NI) 1.56
- Net Margin Trend 20.4% vs 5.5%
- Piotroski F-Score 8/9
Nicht bestanden (4)
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 3.9%
Nicht verfügbar (3)
- Dividend Payout NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Starke finanzielle Gesundheit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Marc A. Stapley | CEO & Director | 55 |
| Ms. Rebecca Chambers | Executive VP & CFO | 47 |
| Dr. Phillip G. Febbo M.D. | Chief Scientific & Medical Officer | 59 |
| Ms. Annie McGuire | Executive VP, General Counsel & Head of Market Access | 44 |
| Dr. John Leite Ph.D. | Global Chief Commercial Officer | 53 |
| Dr. Keith Gligorich Ph.D. | Senior Vice President of Global Operations | - |
| Mr. Jonathan Wygant | VP & Chief Accounting Officer | 54 |
| Dr. Kevin Richard Haas Ph.D. | Chief Development and Technology Officer | 40 |
| Mr. Steven French | Senior VP & Chief Information Officer | - |
| Ms. Kelly Gura | Director of Investor Relations | - |
Prüfungsrisiko
2
Vorstandsrisiko
2
Vergütungsrisiko
5
Aktionärsrechterisiko
4
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for VCYT, sourced from Markets Gazette.
- 2/25/2026NEUTRALVeracyte (VCYT) Q4 2025 Earnings Call Transcript
Investors are keenly awaiting the transcript of Veracyte Inc.'s (VCYT) Q4 2025 earnings call, scheduled for February 25, 2026. While the announcement of such an event is standard for publicly traded companies, the current unavailability of the actual transcript content prevents any in-depth analysis of the financial data, future outlook, or strategic decisions discussed. The eventual release of these details will be crucial for understanding the company's performance and projections, potentially influencing market sentiment and investment decisions. Without this information, the market remains in a holding pattern, awaiting further clarity.
via Markets Gazette